| Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria |
|
Hematology. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes with ring sideroblasts |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
| Controversies on the Consequences of Iron Overload and Chelation in MDS |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
| Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation? |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
| Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
| Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
|
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
|
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis |
|
Haemotologica |
Myelodysplastic Syndromes (MDS) |
| Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society of Blood and Marrow Transplantation |
|
Haematologica |
Aplastic Anemia |
